Skip to content

LAIVAPHAR

Active Public limited companyfounded 1996active for 29 yearsBeauduinstraat 120, 3300 TienenKBO/BCE: BE 0459.291.139 subsidiary of

Lifetime

20 annual accounts with figures on one time axis, 29 filings since 1997
peak of €102,944 in 2024
€101,142previous year 15 months
lowest -€89,110 in 2013
€43,146previous year 15 months
peak of €378,962 in 2025
€378,962▲ 12.8%
€300,291▼ 13.6%
peak of 0.7 FTE in 2006
-not published
Board6 names since 2012
1 director
Owners
99.92%
Documentsfilings and deeds
28-07-20263 days before the deadline
2025micro format
Equity from €335,815 to €378,962Cash from €28,834 to €47,036

Key points

from the 2025 annual accounts

Equity

€378,962 ▲ 12.8%

LAIVAPHAR has made a profit without a break since 2018.

Turnover

≈ €360,000 estimated

The micro format states no turnover.

Position in the sector

€378,962

More equity than 93% of companies in retail trade. Sector median €40,852 · 25,371 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,147 companies had the same profile as LAIVAPHAR has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,147 companies, not a prediction for LAIVAPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 14-03-2024
  • 99.92%equity €68,357 (2025) · annual accounts 2025 of
Board & ownership

Recent changes

3 directors resigning, 1 reappointment , and resign · acts as permanent representative · reappointed as director · General meeting of 14-03-2024 · Gazette deed
3 directors reappointed , (managing director) and · acts as permanent representative · General meeting of 24-01-2020 · Gazette deed
3 directors appointed, 3 resignations (managing director), and appointed · , (managing director) and resign · acts as permanent representative · General meeting of 31-10-2012 · Gazette deed
Amendment of the articles Capital €61,973, annual accounts 2012 · Gazette deed
All 45 events

Comparable companies

same main activity, similar in size and age
Company
LAIVAPHAR Tienen €679,253 €101,142 55.8% -
APOTHEEK VAN GLABEKE Eeklo €763,636 €104,967 25.4% 0
VAN DE WEYER APOTHEEK Landen €661,590 €123,286 88.6% 0.9
DIAPHARMA Leuven €600,343 €105,503 59.5% -
APOTHEEK BEYEN Houthalen-Helchteren €678,116 €112,365 84.2% 0.2
PHARMACIE DUBOIS NORTIER Verviers €643,636 €87,352 83.8% 0.3
APOTHEEK MOEREMANS Ninove €590,537 €102,118 54.5% -

These companies have the same main activity as LAIVAPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €591,000 and €764,000, founded between 1993 and 2001.

Official details

Source: KBO
Status
Active since 22-11-1996Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.080.944.6613300 Tienen, since 20-03-1997
Financial year end
31 December
Peppol
Reachable
Company details

Annual accounts 2025

€679,253▼ 0.6%
Filing
Filed on 28-07-2026, 3 days before the end of the filing period
Financials

Insights on LAIVAPHAR

LAIVAPHAR files the micro format. That format states no turnover. The gross margin rose from €55,081 in 2006 to €101,142 in 2025.

The balance sheet grew most from 2013 to 2014 through fixed assets.

holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about LAIVAPHAR

What is the company number of LAIVAPHAR?
The company number of LAIVAPHAR is 0459.291.139. The VAT number is the same number with BE in front: BE 0459.291.139.
Where is LAIVAPHAR based?
The registered office is at Beauduinstraat 120, 3300 Tienen.Company details
What does LAIVAPHAR do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of LAIVAPHAR?
LAIVAPHAR is a public limited company (NV).
When was LAIVAPHAR founded?
LAIVAPHAR was founded on 22-11-1996.
Is LAIVAPHAR still active?
Yes, LAIVAPHAR is an active enterprise in the KBO register.
What is the turnover of LAIVAPHAR?
The turnover in financial year 2025 is ≈ €360,000. This figure is estimated from the gross margin of €101,142 and 38 comparable companies (NACE 477). It probably lies between €270,000 and €590,000.Financials
Is LAIVAPHAR profitable?
In financial year 2025, LAIVAPHAR made a profit of €43,146.
Where can I find the annual accounts of LAIVAPHAR?
LAIVAPHAR filed 29 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of LAIVAPHAR due?
LAIVAPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.